Belarusian State Medical University, Minsk, Belarus.
Republican Scientific and Practical Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus.
Dokl Biochem Biophys. 2022 Dec;507(1):307-311. doi: 10.1134/S1607672922050076. Epub 2023 Feb 14.
In the present study, the effect of nortriptyline (1 and 10 μM), budesonide (10 nM) and their combination on the migration of peripheral blood lymphocytes and monocytes from patients with chronic obstructive pulmonary disease (COPD) towards chemokines CCL5 and CXCL10 was evaluated by flow cytometry. Nortriptyline (10 μM), both alone and in combination with budesonide, inhibited the migration of T helper cells, cytotoxic T lymphocytes, NK cells and B lymphocytes towards CCL5 and CXCL10, as well as enhanced monocyte migration towards these chemokines. The combination of nortriptyline (1 μM) and budesonide suppressed the chemotaxis of lymphocyte subpopulations towards CXCL10, but not towards CCL5, more effectively than budesonide alone. The combination of nortriptyline (10 μM) and budesonide inhibited the migration of lymphocyte subpopulations towards CCL5 and CXCL10 and activated monocyte chemotaxis towards both chemokines more effectively than budesonide alone. The results of this study demonstrate the ability of nortriptyline alone to modulate the migration of peripheral blood lymphocytes and monocytes from patients with COPD and to potentiate the effects of budesonide.
在本研究中，通过流式细胞术评估了去甲替林（1 和 10 μM）、布地奈德（10 nM）及其组合对慢性阻塞性肺疾病（COPD）患者外周血淋巴细胞和单核细胞向趋化因子 CCL5 和 CXCL10 迁移的影响。去甲替林（10 μM）单独或与布地奈德联合使用，可抑制 T 辅助细胞、细胞毒性 T 淋巴细胞、NK 细胞和 B 淋巴细胞向 CCL5 和 CXCL10 的迁移，并增强单核细胞向这些趋化因子的迁移。去甲替林（1 μM）与布地奈德联合使用可更有效地抑制淋巴细胞亚群向 CXCL10 的趋化作用，而不是向 CCL5 的趋化作用，而不是布地奈德单独使用。去甲替林（10 μM）与布地奈德联合使用可更有效地抑制淋巴细胞亚群向 CCL5 和 CXCL10 的迁移，并激活单核细胞向两种趋化因子的趋化作用，优于布地奈德单独使用。本研究的结果表明，去甲替林单独能够调节 COPD 患者外周血淋巴细胞和单核细胞的迁移，并增强布地奈德的作用。
